Analyst Recommendation Trends
Wall Street analyst consensus for ICU over the last few months:
Latest ICU News
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, t
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock rose
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE ® (SCD-PED) therapy Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy DENVER, Oct. 01, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss o
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
Dr. Chung to deliver an oral presentation highlighting QUELIMMUNE®, an advanced extracorporeal therapy for critically ill pediatric patients with acute kidney injury (AKI) DENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that its Chief Medical Officer, Kevin Chung, M.D., will deliver a
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy
Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute kidney injury (AKI) SeaStar Medical’s SCD development pipeline of indications holds promise for multiple additional indications DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformati
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City. The SeaStar Medical presentatio
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-18 | Messinger Michael | +750 | $3.27 | $2,453 |
| 2026-07-01 | Schlorff Eric | +10,288 | - | - |
| 2026-07-01 | Chung Kevin | +7,202 | - | - |
| 2026-07-01 | Vincent Bernadette N | +4,000 | - | - |
| 2026-07-01 | Neuman John | +4,000 | - | - |
| 2026-07-01 | Baird Jennifer A | +4,000 | - | - |
| 2026-07-01 | Van Heel Kenneth | +4,000 | - | - |
| 2026-02-06 | Neuman John | +3,000 | - | - |
| 2026-02-06 | Vincent Bernadette N | +3,000 | - | - |
| 2026-02-06 | Baird Jennifer A | +3,000 | - | - |
| 2026-02-06 | Chung Kevin | +15,000 | - | - |
| 2026-02-06 | Schlorff Eric | +30,000 | - | - |
| 2026-02-06 | Towne Bradford K | +7,500 | - | - |
| 2026-02-06 | Van Heel Kenneth | +3,000 | - | - |
| 2025-12-19 | Baird Jennifer A | +4,200 | $0.2351 | $987 |
| 2025-12-09 | Messinger Michael | +14,500 | $0.3516 | $5,098 |